The Somatostatin Receptor Type 2 pipeline drugs market research report outlays comprehensive information on the Somatostatin Receptor Type 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Somatostatin Receptor Type 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Hormonal Disorders, Metabolic Disorders, and Gastrointestinal which include the indications Neuroendocrine Tumors, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Acromegaly, Growth Hormone Deficiency, Hypoglycemia, Nocturnal Hypoglycemia, Liver Diseases, and Zollinger-Ellison Syndrome (Gastrinoma). It also reviews key players involved in Somatostatin Receptor Type 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Somatostatin Receptor Type 2 pipeline targets constitutes close to 38 molecules. Out of which, approximately 38 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 3, 7, 9, 7, 7, and 3 respectively.
Somatostatin Receptor Type 2 overview
Somatostatin receptor type 2 is a protein that encoded by the SSTR2 gene. Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. SSTR2 is expressed in highest levels in cerebrum and kidney.
For a complete picture of Somatostatin Receptor Type 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
